ArticleScientific reports2016
Fragment-based de novo design of a cystathionine γ-lyase selective inhibitor blocking hydrogen sulfide production.
Article in Scientific reports, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 25 citations in OpenAlex.
- Hydrogen sulfide regulation in redox homeostasis and programmed cell death: mechanistic insights and implications in cancer.Journal of advanced research · 2026Review
- Pharmacological inhibition of hydrogen sulfide production mitigates constipation in a type 1 diabetes mouse model.Scientific reports · 2026Article
- Crosstalk Between HHandbook of experimental pharmacology · 2026Review
- A H2S-activated NIR-II imaging probe for precise diagnosis and pathological evaluation of colorectal tumor.Theranostics · 2025Article
- Pills of Multi-Target HInternational journal of molecular sciences · 2024Review
- Mechanism-based and computational modeling of hydrogen sulfide biogenesis inhibition: interfacial inhibition.Scientific reports · 2023Article
- Methods for Suppressing Hydrogen Sulfide in Biological Systems.Antioxidants & redox signaling · 2022Review
- HBiomolecules · 2021Review
- The Hidden Role of Hydrogen Sulfide Metabolism in Cancer.International journal of molecular sciences · 2021Review
- Trends in HAntioxidants (Basel, Switzerland) · 2021Review
- Structure-activity relationships study of isothiocyanates for HJournal of advanced research · 2021Review
- The Role of Host-Generated HFrontiers in cellular and infection microbiology · 2020Review
- 2-Arylidene Hydrazinecarbodithioates as Potent, Selective Inhibitors of Cystathionine γ-Lyase (CSE).ACS medicinal chemistry letters · 2017Article
- Fluorescent Probes and Selective Inhibitors for Biological Studies of Hydrogen Sulfide- and Polysulfide-Mediated Signaling.Antioxidants & redox signaling · 2017Review
- International Union of Basic and Clinical Pharmacology. CII: Pharmacological Modulation of HPharmacological reviews · 2017Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors at 4 institutions in 3 countries.
Funding
Abstract
Hydrogen sulfide is an essential catabolite that intervenes in the pathophysiology of several diseases from hypertension to stroke, diabetes and pancreatitis. It is endogenously synthesized mainly by two pyridoxal-5'-phosphate-dependent enzymes involved in L-cysteine metabolism: cystathionine-ß-synthase (CBS) and cystathionine-γ-lyase (CSE). Research in this field is currently impaired by the lack of pharmacological tools such as selective enzymatic inhibitors that could target specifically only one of these pathways. We used a novel approach based on a hybrid method that includes drug design, synthetic biology, metabolomics and pharmacological assays to rationally design a new inhibitor selective for the CSE enzyme. The identification of this compound opens new frontiers towards a better understanding of the role of CSE over CBS in the pathophysiology of diseases where a role for the H
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.